May 2008

Promote your expertise

May 29, 2008

Did you know that BiotechBlog posts are syndicated to outlets such as Reuters, Biospace, San Francisco Gate, Chicago Sun-Times, and dozens of other media outlets? BiotechBlog provides a forum to promote your expertise through the publication of actionable industry guidance. See guest content and the submission guidelines for more information Share this page

Read the full article →

Call for papers: Biotechnology Investing

May 29, 2008

The Journal of Commercial Biotechnology is looking for papers on investing strategies in the biotechnology space. The scope can include valuation models, strategies to identify under-valued companies, case studies in developing and managing a portfolio, etc. The Journal of Commercial Biotechnology is a peer-reviewed journal focused on the business of biotechnology. More information, instructions for [...]

Read the full article →

BIO2008 book signing

May 21, 2008

For those attending BIO2008 in San Diego this year, I’ll be doing a signing of my books on Wednesday June 18th from 10-11. There will also be a limited number of free copies of the Journal of Commercial Biotechnology, so be sure and show up early! I’ll also be speaking on Friday morning: Title: Scientific [...]

Read the full article →

Seeking reviewers and contributors for next edition of Building Biotechnology

May 15, 2008

I’ve nearly completed revisions for the third edition of Building Biotechnology, the leading textbook on the business of biotechnology. This new edition has several new chapters, new case studies, updated case law, and fresh industry stats — more than 100 pages longer than the second edition. I’m looking for volunteers to review the chapters and [...]

Read the full article →

Dyadic founder fights to regain control of company

May 11, 2008

The science of biotechnology is tough. R&D can be unpredictable, and most products need regulatory approval before they can be sold. But biotechnology companies also need to worry about other problems, like management issues. The case of Dyadic’s illustrates some of the often-overlooked challenges in commercializing biotechnology. Mark Emalfarb founded Dyadic in 1979 as a [...]

Read the full article →

Drug Patent Expirations in May 2008

May 6, 2008

Courtesy of DrugPatentWatch.com: Drug Patent Expirations in May 2008 *Drugs may be covered by multiple patents Tradename Applicant Generic Name Patent Number Patent Expiration HABITROL Novartis nicotine 5,016,652 May 21, 2008 REQUIP Glaxosmithkline ropinirole hydrochloride 4,824,860 May 19, 2008 SARAFEM Lilly fluoxetine hydrochloride 4,971,998 May 20, 2008 Courtesy of DrugPatentWatch.com

Read the full article →